AMGN Amgen Inc.

Price (delayed)

$216.94

Market cap

$126.3B

P/E Ratio

17.37

Dividend/share

$6.25

EPS

$12.49

Enterprise value

$151.5B

Sector: Healthcare
Industry: Drug Manufacturers - General
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Highlights

The P/E is 28% below the 5-year quarterly average of 24.1 and 6% below the last 4 quarters average of 18.5
The revenue has grown by 7% year-on-year and by 2.8% since the previous quarter
AMGN's quick ratio is down by 28% year-on-year but it is up by 3.1% since the previous quarter
The debt rose by 15% year-on-year
The net income has contracted by 9% YoY

Key stats

What are the main financial stats of AMGN
Market
Shares outstanding
582.17M
Market cap
$126.3B
Enterprise value
$151.5B
Valuations
Price to earnings (P/E)
17.37
Price to book (P/B)
11.59
Price to sales (P/S)
5.08
EV/EBIT
15.97
EV/EBITDA
11.73
EV/Sales
6.06
Earnings
Revenue
$24.99B
EBIT
$9.48B
EBITDA
$12.91B
Free cash flow
$10.24B
Per share
EPS
$12.49
Free cash flow per share
$17.5
Book value per share
$18.71
Revenue per share
$42.71
TBVPS
$55.91
Balance sheet
Total assets
$64.64B
Total liabilities
$53.68B
Debt
$34.29B
Equity
$10.96B
Working capital
$12.71B
Liquidity
Debt to equity
3.13
Current ratio
2.28
Quick ratio
1.65
Net debt/EBITDA
1.95
Margins
EBITDA margin
51.7%
Gross margin
76.7%
Net margin
29.4%
Operating margin
36.7%
Efficiency
Return on assets
11.7%
Return on equity
72.1%
Return on invested capital
22%
Return on capital employed
17.3%
Return on sales
38%
Dividend
Dividend yield
2.88%
DPS
$6.25
Payout ratio
50%

AMGN stock price

How has the Amgen stock price performed over time

Financial performance

How have Amgen's revenue and profit performed over time
Revenue
$24.99B
Gross profit
$19.17B
Operating income
$9.18B
Net income
$7.35B
Gross margin
76.7%
Net margin
29.4%
The net margin has declined by 15% year-on-year and by 2% since the previous quarter
The company's operating margin fell by 14% YoY and by 3.2% QoQ
The net income has contracted by 9% YoY
AMGN's operating income is down by 8% year-on-year

Growth

What is Amgen's growth rate over time

Valuation

What is Amgen stock price valuation
P/E
17.37
P/B
11.59
P/S
5.08
EV/EBIT
15.97
EV/EBITDA
11.73
EV/Sales
6.06
The P/E is 28% below the 5-year quarterly average of 24.1 and 6% below the last 4 quarters average of 18.5
AMGN's EPS is down by 4.7% year-on-year
The stock's price to book (P/B) is 47% more than its 5-year quarterly average of 7.9 but 14% less than its last 4 quarters average of 13.5
Amgen's equity has increased by 2.8% from the previous quarter
The P/S is 11% less than the last 4 quarters average of 5.7 and 6% less than the 5-year quarterly average of 5.4
The revenue has grown by 7% year-on-year and by 2.8% since the previous quarter

Efficiency

How efficient is Amgen business performance
AMGN's return on sales is down by 17% year-on-year and by 3.6% since the previous quarter
AMGN's return on assets is down by 9% year-on-year
The ROIC has grown by 9% YoY but it has contracted by 2.2% from the previous quarter

Dividends

What is AMGN's dividend history
DPS
$6.25
Dividend yield
2.88%
Payout ratio
50%
Recent dividends

Financial health

How did Amgen financials performed over time
Amgen's total assets is 20% more than its total liabilities
AMGN's quick ratio is down by 28% year-on-year but it is up by 3.1% since the previous quarter
Amgen's current ratio has decreased by 21% YoY but it has increased by 4.6% from the previous quarter
AMGN's debt to equity is up by 15% YoY but it is down by 2.5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.